Extinction level event Self disseminating self-replicating and spreading vaccines patents, coronavirus patents, MRNA and RNA vaccine patents mRNA lipid nanoparticles patents influenza vaccine patent s

Just unpacking it all All the way down to the viral vectors of the new vaccines for influenza

Back in February I did this article but I don't think it was taken seriously enough Let's try it again Self-disseminating vaccines for emerging infectious diseases A Extinction level event!  As self-spreading vaccine technology moves forward, dialogue on its risks should follow, And that is an understatement! And it all started with the requirement that may provide a potential ‘window of opportunity’ for immunological targeting of the pathogen within the animal transmission species, they say, And you wonder why all the animals were walking endlessly in circles this last year It's all over YouTube ,

thereby stemming its continued zoonotic flow prior to acquisition of full adaptation to humans. Self-disseminating vaccines are a vaccine strategy that may in some instances be better suited than conventional vaccines to immunologically contain emerging pathogens within their non-human host in challenging under-resourced ‘hotspots’ they say and are totally delusional What if that self spreading vaccine killed every virus in the world everybody in the world would die The whole ecosystem in the world would die. Disseminating vaccines are designed to exploit the ability of replicating virus-based vectors to spread through their animal host populations without the need for direct inoculation of every animal. In this strategy, vaccination of a limited number of ‘founder’ animals is used for initial introduction of the vaccine into the target population. As the vaccine is engineered to express target antigens from the EID pathogen of interest, its spread from vaccinated to non-vaccinated animals and will result in coordinated spread of EID-specific immunity throughout the targeted animal population. What a bunch of idiots! With a great idea! NOT  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732410/  Researchers are developing controversial self-spreading vaccines for wildlife; according to this report One-third of unvaccinated hospitalized patients with covid-19 still express vaccine hesitancy. yep that's me And yep that makes me a target and a perfect candidate for ursulization program, We must prepare for future zoonotic outbreaks they say, While there is a justified urgent focus on developing vaccines and antivirals to limit the spread and severity of SARS-CoV-2 infections, And now it's the damn bird flu and we all know it's created in a lab and spread It's not made by nature and it never will be, it is essential to determine the factors that drive zoonotic disease emergence. They try to fool us into thinking that the factors could be anything because they make it up as they go,Knowing why and how zoonotic diseases emerge in humans facilitates pandemic preparation and prevention. To mitigate future pandemics, more effective surveillance at the animal-human interface is fundamental, and the wildlife trade and live animal markets must be heavily regulated and monitored. Yeah like pumping all the cows full of nanotech to track and trace every move and buy registering every chicken you have. Sustainable environments for wildlife away from population centers and a global “pandemic radar” system to share information rapidly regarding zoonotic events and disease outbreaks are critical to mitigate future pandemic threats, they say.  https://onehealthtrust.org/news-media/weekly-digest/controversial-self-spreading-vaccines-for-wildlife/ Scientists in Scotland recently penned the latest installment in the literature about the quest for self-spreading vaccines, inoculations that could move through animal populations like a disease, but instead of illness, spread immunity. In a new article, University of Glasgow researcher Megan Griffiths and her colleagues identified a herpes virus that might be turned into a vehicle known as a viral vector to spread a rabies vaccine among South American vampire bats. The herpes virus Griffiths highlighted could potentially help researchers overcome a big hurdle for self-spreading vaccine development: Pre-existing immunity to a viral vector used for a vaccine, induced by previous infection with the virus or a related strain, may block the vaccine from spreading. Griffiths’s team studied a herpes virus that can infect bats even if they were previously infected by related strains and therefore could still be an effective viral vector. https://thebulletin.org/2022/06/as-self-spreading-vaccine-technology-moves-forward-dialogue-on-its-risks-should-follow/     

                  Rise of the RNA machines – self-amplification in mRNA vaccine design.  A next generation of self-amplifying mRNAs, also known as replicons, form an ideal vaccine platform.

Replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or lipid nanoparticles. Here, we discuss innovative advances, including multivalent, mucosal, and therapeutic replicon vaccines, and highlight novelties in replicon design. As soon as essential safety evaluations have been resolved, this promising vaccine concept can transform into a widely applied clinical platform technology taking center stage in pandemic preparedness. Whereas mRNA vaccines encode a protein of interest, replicons have been engineered as a molecular chassis encoding the gene of interest (GOI; transgene) and all essential elements allowing self-amplification of the replicon RNA. The rapid amplification of replicon RNA in target cells increases the expression of the protein of interest (e.g., a viral (glyco)protein) The self-amplifying replicon genes have been derived from a wide variety of positive-stranded RNA viruses. In this review, we focus on alpha- and flavivirus-based replicons as they are best studied for both human and veterinary applications. Because the viral structural genes have been replaced by a transgene, the replicon RNA cannot spread in the environment, which is a key difference with chimeric or recombinant virus vaccines,First, as the transgene is synthetically derived and the replicon cannot spread, replicon manufacturing processes have low biocontainment restrictions and application is safe-by-design, Second, the transgene can simply be inserted into the ‘plug-and-play’ replicon (e.g., the commercially available Simplicon plasmid of Merck/Sigma–Aldrich), allowing rapid application in case of emerging infectious disease outbreaks. Finally, due to the self-amplifying character of the replicon vaccine, both humoral and cellular immune responses are triggered, which promises induction of protective immunity with a single low-dose immunization The most straightforward replicon formulation is based on naked delivery of the nucleic acids to the target cell.The natural tropism of these particles, which are structurally similar to a virus, enables the efficient delivery of the replicon to dendritic cells (direct priming) or target cells that indirectly prime antigen-presenting cells, resulting in the induction of a robust immune response Although the genetic cargo of the VRP consists of replicon RNA, which is limited to a single round of transduction, there is an anticipated risk of recombination between the replicon RNA and the trans-provided helper RNA resulting in the generation of replication-competent virus Although vaccination with alphavirus or flavivirus VRPs can trigger vector-immune responses, these did not adversely influence the vaccine efficiency after repetitive vaccinations with the same VRP However, to fully exclude antivector immunity, nonviral and lipid-based carriers for replicon RNA delivery can be considered. a combination known as nanostructured-lipid carriers (NLCs). Similar to liposomes, the lipid membrane of LNPs allows for additional modification to either the surface as well as the drug cargo itself a combination known as nanostructured-lipid carriers

(NLCs). Similar to liposomes, the lipid membrane of LNPs allows for additional modification to either the surface as well as the drug cargo itself. In the early race for nucleic acid vaccines, the primary focus was on DNA instead of RNA. In the case of replicon vaccines, a prerequisite of the in vitro transcription of replicon RNA is a DNA template. The replicon RNA is then transported to the cytoplasm as a capped mRNA and is translated to initiate self-amplification, similar to the direct delivery of in vitro transcribed replicon RNA , A DREP shows less susceptibility to nucleases, is intrinsically more stable, and simplifies storage requirements in the logistic pipeline. However, the delivery of naked plasmid DNA to the nucleus is more challenging than the delivery of mRNA to the cytoplasm  A potential safety concern of DNA vaccines is the theoretical risk of DNA vector integration into the host genome or adverse (health) effects of prokaryotic elements. Confidence in replicon platform registration in the veterinary field will help establishing similar procedures for the human vaccine field. Recently, the first human replicon vaccine was granted an Emergency Use Approval by Indian regulators (Central Drugs Standard Control Organization; CDSCO). This CDSCO-approved VEEV-TC83-based replicon vaccine expresses a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike gene and is encapsulated in LNPs (license number MF/BIO/22/000064 under PD/Vacc-06).  Global authorization of alphavirus- and flavivirus-based replicon vaccines is expected now that others have paved the way. The USDA-approved VEEV-TC83 replicon vaccine already showed successful utilization in the immunization of millions of animals against a swine coronavirus Furthermore, a live-attenuated, chimeric flavivirus vector vaccine platform (ChimeriVax) is commercially available in Australia, Thailand, Mexico, the Philippines, and Brazil,,  Even if the replicon spreads to the fetus, it is not expected to affect the development of the fetus as was shown for an attenuated YFV17D vector vaccine   The replicon vector technology is constantly advancing. One recent development is the establishment of a bipartite replicon vector system  http://www.google.com/patents/sitemap/en/Sitemap/C12/C12N/C12N_7_53.html  To take this further, in theory an RNA-dependent RNA polymerase (RdRp) in combination with the essential 5′ and 3′ noncoding regions at the replicon RNA termini is sufficient for self-amplification. Viral genomes with RdRps sized ~2 kb are present in nature  and these may inspire future replicon design.  Where as a monopartite replicon encodes the self-amplifying genes and the transgene on one RNA strand, the bipartite replicon expresses the protein of interest from a trans-amplifying RNA.  However, additional preclinical and clinical studies are required to safeguard the implementation of replicon vaccines in vulnerable individuals. If antigen ratios are less important and a platform technology is in place, multivalent replicon vaccine formulations can combat dynamic virus outbreaks, for example, SARS-CoV-2 with novel variants continuously emerging from biolabs across the world. The paradigm shift in the vaccine field from protein to mRNA will definitely help to mature replicon technology in general and promote the further improvement of these sophisticated RNA machines. I think a monkey just flew out my butt

And list seems to go on and on and on and on and on and on and on and on and on and on and on just in case I didn't make myself clear on just how damn dangerous these things are to all of humanity and all of creations check out these videos

  https://rumble.com/v50h3lz-warning-this-october-launch-of-new-mrna-replicon-with-replicating-machinery.html                         

   https://rumble.com/v4gwezl-darpa-to-create-self-spreading-airborne-vaccines-and-more.html                             

     https://rumble.com/v4wfiyf-self-assembling-nano-in-geoengineering-spray-and-meat-with-dr.-ana-mihalcea.html               And with this plannedpandemic of the bird influenza virus The European Commission's Health Emergency Preparedness and Response Authority (HERA) tapped CSL Seqirus to deliver 665,000 doses of its pre-pandemic bird flu vaccine for 15 European countries. Under a four-year contract, authorities can purchase up to 40 million more doses. And with the 9th circuit court just ruling that vaccines from the COVID-19 bio weapon spread and made your body produce the virus so called spike protein that created the pandemic How long do you think it's going to take from the 40 million doses to spread the bird flu influenza virus pretty interesting the CSL seqirus only has six patent's   And they all have to do with the influenza virus It's like it's all been planned out All the way down to the two proteins that they make your body create the viral vectors gain a function

Thanks for all that you do to stop this biohack on all that is natural and made in the image of GOD and may Romans 8:31 be our guiding light. 6831